NICOTINAMIDE TABLETS 100MG
Active substance(s): NICOTINAMIDE / NICOTINAMIDE / NICOTINAMIDE
NAME OF THE MEDICINAL PRODUCT
Nicotinamide Tablets 100 mg
QUALITATIVE AND QUANTITATIVE COMPOSITION
Nicotinamide BP 100 mg
Treatment of nicotinic acid deficiency.
Posology and method of administration
Adults, the elderly and children over twelve years
One to three tablets daily in divided doses.
Children under twelve years
Route of administration
Special warnings and precautions for use
Interaction with other medicinal products and other forms of interaction
Fertility, pregnancy and lactation
Nicotinamide is acceptable for use in pregnancy and lactation at normal doses.
Effects on ability to drive and use machines
Overdose with nicotinamide does not appear to have been reported. Adverse
effects of the related nicotinic acid are usually not serious and subside on
withdrawal of the drug.
Nicotinamide is converted in the body to the enzymes nicotinamide adenine
dinucleotide and nicotinamide adenine dinucleotide phosphate which are
involved in electron transfer reactions in the respiratory chain.
Nicotinamide is readily absorbed from the gastro-intestinal tract following oral
administration and widely distributed in the body tissues. The main route of
metabolism is conversion to n-methylnicotinamide and the 2-pyridone and 4pyridone derivatives; nicotinuric acid is also formed. Small amounts of
nicotinamide are excreted unchanged in urine following therapeutic doses;
however the amount excreted unchanged is increased with larger doses.
Preclinical safety data
No relevant data.
List of excipients
Vegetable Fatty Acid
Gum Acacia (as 10% mucilage)
Special precautions for storage
In well closed containers, in a dry place protected from light.
Nature and contents of container
High impact polystyrene white or polystyrene amber co-plastic bottles.
Pack size: 100 and 1000 tablets
Special precautions for disposal
MARKETING AUTHORISATION HOLDER
Nutrition Warehouse Limited
Samuel Ryder House
MARKETING AUTHORISATION NUMBER(S)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
1st October 1999
DATE OF REVISION OF THE TEXT
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.